JonesTrading Sticks to Its Buy Rating for Aeglea Biotherapeutics Inc (AGLE)

By Ryan Adsit

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Aeglea Biotherapeutics Inc (AGLEResearch Report), with a price target of $16. The company’s shares closed last Monday at $7.72.

Roy wrote:

“Aegl ea ’s mature Phase 1/2 20-dose data today continued to show robust and durable clinical benefits in patients with arginase deficiency (poster link bit.ly/2lUudoN) — (1) 70% reduction in plasma arginine levels, bringing mean levels almost within normal range, (2) a combined mobility response rate of 79% (11/14), in line with our estimate of approx.”

According to TipRanks.com, Roy has 0 stars on 0-5 star ranking scale with an average return of -19.2% and a 24.6% success rate. Roy covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Neon Therapeutics Inc, and Surface Oncology Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aeglea Biotherapeutics Inc with a $18 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $11.11 and a one-year low of $5.99. Currently, Aeglea Biotherapeutics Inc has an average volume of 147.5K.

Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGLE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.